Luca Gianni

Summary

Affiliation: Istituto Nazionale Tumori
Country: Italy

Publications

  1. ncbi request reprint Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails
    Cristiana Sessa
    Southern Europe New Drugs Organization Foundation, Via Visconti di Modrone 12, 20100 Milano, Italy
    J Clin Oncol 23:1867-74. 2005
  2. ncbi request reprint Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes
    Luca Gianni
    Division of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, ViaVenezian 1, Milan 20133, Italy
    Cardiovasc Toxicol 7:67-71. 2007
  3. doi request reprint Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer
    Luca Gianni
    Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    J Clin Oncol 27:2474-81. 2009
  4. doi request reprint Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastat
    Luca Gianni
    Oncologia Medica 1, Istituto Nazionale Tumori, Via Venezian, 1, 20133 Milano, Italy
    J Clin Oncol 28:1131-7. 2010
  5. doi request reprint Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
    Luca Gianni
    Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Lancet 375:377-84. 2010
  6. ncbi request reprint Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy
    Luca Gianni
    Istituto Nazionale Tumori, Milan, Italy, and Hospital Vall d Hebron, Barcelona, Spain
    Clin Cancer Res 11:8715-21. 2005
  7. doi request reprint Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
    Gabriella Mariani
    Department of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy
    Nat Clin Pract Oncol 6:93-104. 2009
  8. pmc 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study
    Gianni Bonadonna
    Istituto Nazionale Tumori, 20133 Milan, Italy
    BMJ 330:217. 2005
  9. ncbi request reprint Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study
    Gabriella Mariani
    Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Clin Breast Cancer 7:321-5. 2006
  10. ncbi request reprint Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer
    Gianni Bonadonna
    Department of Medical Oncology, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
    J Clin Oncol 22:1614-20. 2004

Detail Information

Publications46

  1. ncbi request reprint Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails
    Cristiana Sessa
    Southern Europe New Drugs Organization Foundation, Via Visconti di Modrone 12, 20100 Milano, Italy
    J Clin Oncol 23:1867-74. 2005
    ..To assess the efficacy and toxicity of the marine-derived alkaloid trabectedin (ET-743) in patients with advanced ovarian cancer refractory to or experiencing disease relapse after platinum- and taxane-based chemotherapy...
  2. ncbi request reprint Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes
    Luca Gianni
    Division of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, ViaVenezian 1, Milan 20133, Italy
    Cardiovasc Toxicol 7:67-71. 2007
    ....
  3. doi request reprint Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer
    Luca Gianni
    Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    J Clin Oncol 27:2474-81. 2009
    ..To evaluate the addition of paclitaxel to an anthracycline-based adjuvant regimen and to compare this combination with the same regimen given as primary systemic (neoadjuvant) therapy...
  4. doi request reprint Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastat
    Luca Gianni
    Oncologia Medica 1, Istituto Nazionale Tumori, Via Venezian, 1, 20133 Milano, Italy
    J Clin Oncol 28:1131-7. 2010
    ..The utility of biomarkers detected in paraffin-embedded tissue as predictors of response was also explored...
  5. doi request reprint Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
    Luca Gianni
    Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Lancet 375:377-84. 2010
    ..We aimed to assess event-free survival in patients with HER2-positive locally advanced or inflammatory breast cancer receiving neoadjuvant chemotherapy with or without 1 year of trastuzumab...
  6. ncbi request reprint Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy
    Luca Gianni
    Istituto Nazionale Tumori, Milan, Italy, and Hospital Vall d Hebron, Barcelona, Spain
    Clin Cancer Res 11:8715-21. 2005
    ..We report here feasibility, tolerability, locoregional antitumor activity, and breast conservation rate...
  7. doi request reprint Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
    Gabriella Mariani
    Department of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy
    Nat Clin Pract Oncol 6:93-104. 2009
    ..Current data do not support the use of trastuzumab for more than 1 year. The analysis of 2-year treatment with trastuzumab is expected to be available in 2009...
  8. pmc 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study
    Gianni Bonadonna
    Istituto Nazionale Tumori, 20133 Milan, Italy
    BMJ 330:217. 2005
    ....
  9. ncbi request reprint Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study
    Gabriella Mariani
    Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Clin Breast Cancer 7:321-5. 2006
    ....
  10. ncbi request reprint Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer
    Gianni Bonadonna
    Department of Medical Oncology, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
    J Clin Oncol 22:1614-20. 2004
    ..To assess the clinical relevance of different sequences of doxorubicin (DOX) and cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients with operable breast cancer at risk of disease relapse...
  11. ncbi request reprint Cardiotoxic effects of anthracycline-taxane combinations
    Antonella Perotti
    Division of Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumouri, 20133 Milan, Italy
    Expert Opin Drug Saf 2:59-71. 2003
    ..Furthermore, there are experimental data indicating that DTX can also stimulate the metabolism of DOX to toxic species in human heart...
  12. ncbi request reprint Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer
    Giulia Bianchi
    Istituto Nazionale Tumori, Milan, Italy
    Clin Cancer Res 9:5944-51. 2003
    ..This pilot study evaluates the efficacy and cardiac tolerability of AT followed by paclitaxel with trastuzumab started with AT or paclitaxel alone and investigates pharmacokinetic interactions...
  13. doi request reprint Role of anthracyclines in the treatment of early breast cancer
    Luca Gianni
    Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 27:4798-808. 2009
    ..To review data relating to anthracyclines in the adjuvant treatment of early breast cancer...
  14. ncbi request reprint Anthracyclines
    Luca Gianni
    Division of Medical Oncology A, Istituto Nazionale Tumori, Milan, Italy
    Cancer Chemother Biol Response Modif 21:29-40. 2003
  15. ncbi request reprint Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level
    Manuela Campiglio
    Molecular Targeting Unit, Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
    J Cell Physiol 198:259-68. 2004
    ..Our data suggest that the antitumor activity of ZD1839 is due to a cytostatic effect, and involves apoptosis induction in a subset of sensitive cells only, and that neither MAPK nor Akt is a reliable marker of ZD1839 activity...
  16. doi request reprint 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
    Aron Goldhirsch
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Lancet 382:1021-8. 2013
    ....
  17. pmc Anthracycline cardiotoxicity: from bench to bedside
    Luca Gianni
    Division of Medical Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Instituto Nazionale Tumori, Milan, Italy
    J Clin Oncol 26:3777-84. 2008
    ..Here, we incorporate these discussions into the framework of a broader review of preclinical and clinical issues...
  18. doi request reprint AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer
    Luca Gianni
    Department of Medical Oncology, San Raffaele Hospital, Via Olgettina 60, Milan, Italy
    J Clin Oncol 31:1719-25. 2013
    ..The potential predictive value of plasma VEGF-A is consistent with findings in HER2-negative LR/MBC, warranting prospective evaluation...
  19. ncbi request reprint Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
    Luca Gianni
    Oncologia Medica, San Raffaele Cancer Centre, Milan, Italy
    Lancet Oncol 13:25-32. 2012
    ..We investigated the combination of pertuzumab or trastuzumab, or both, with docetaxel and the combination of pertuzumab and trastuzumab without chemotherapy in the neoadjuvant setting...
  20. ncbi request reprint The future of targeted therapy: combining novel agents
    Luca Gianni
    Division of Medical Oncology, Istituto Nazionale Tumori, Via Venezian 1, I 20133 Milan, Italy
    Oncology 63:47-56. 2002
    ..It is possible that through the development and use of biological anticancer agents, such as Herceptin, future anticancer regimens may be specifically tailored to each patient based on their molecular characteristics...
  21. ncbi request reprint Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer
    Luca Gianni
    Medical Oncology, Istituto Nazionale Tumori, Via Venezian, 1, 20133 Milano, Italy
    J Clin Oncol 23:7265-77. 2005
    ..We sought to identify gene expression markers that predict the likelihood of chemotherapy response. We also tested whether chemotherapy response is correlated with the 21-gene Recurrence Score assay that quantifies recurrence risk...
  22. ncbi request reprint Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer
    Giulia Bianchi
    Fondazione IRCCS Istituto Tumori di Milano, Via Venezian, 1, 20133 Milan, Italy
    Anticancer Drugs 20:616-24. 2009
    ..Further investigation of single-agent sorafenib in this patient population is not recommended; however, studies investigating combinations of sorafenib with chemotherapeutic agents are warranted and ongoing...
  23. ncbi request reprint Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
    Luca Gianni
    Department of Medical Oncology, San Raffaele Institute, Milan, Italy
    Lancet Oncol 12:236-44. 2011
    ..We aimed to assess disease-free survival and overall survival after a median follow-up of 4 years for patients enrolled on the Herceptin Adjuvant (HERA) trial...
  24. doi request reprint Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours
    Nicola Nicolai
    Urology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    BJU Int 104:340-6. 2009
    ....
  25. doi request reprint Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer
    Giampaolo Bianchini
    Division of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Cancer Res 70:8852-62. 2010
    ..Taken together, our results indicate that kinases regulating mitosis and immune functions convey distinct prognostic information that varies by clinical subtype...
  26. ncbi request reprint Breast cancer: diagnostic and therapeutic options
    Emilio Bombardieri
    Division of Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Eur J Nucl Med Mol Imaging 31:S1-2. 2004
  27. ncbi request reprint The choice of the correct imaging modality in breast cancer management
    Emilio Bombardieri
    Division of Nuclear Medicine, PET Centre, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Eur J Nucl Med Mol Imaging 31:S179-86. 2004
    ..There is a need for further prospective evaluations with appropriate clinical trials designed to evaluate the impact of these approaches in improving survival and quality of life...
  28. ncbi request reprint Anthracyclines
    Luca Gianni
    Istituto Nazionale Tumori, Milan, Italy
    Cancer Chemother Biol Response Modif 20:59-69. 2002
  29. pmc Accurate data processing improves the reliability of Affymetrix gene expression profiles from FFPE samples
    Maurizio Callari
    Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    PLoS ONE 9:e86511. 2014
    ..Tools for the implementation of our data processing algorithm are made publicly available at http://www.biocut.unito.it/cdf-ffpe/. ..
  30. ncbi request reprint Targeting TRAIL agonistic receptors for cancer therapy
    Carmelo Carlo-Stella
    Cristina Gandini Medical Oncology Unit, Istituto Nazionale Tumori, Milan, Italy
    Clin Cancer Res 13:2313-7. 2007
    ..The clinical translation of cell and gene therapy approaches represent a challenging strategy that might achieve systemic tumor targeting and increased intratumor delivery of the therapeutic agent...
  31. ncbi request reprint Targeting the epidermal growth factor receptor a new strategy in cancer treatment
    Luca Gianni
    Progetto Montabone per lo Sviluppo di Nuove Terapie, Istituto Nazionale dei Tumori, Milan, Italy
    Suppl Tumori 1:S60-1. 2002
  32. ncbi request reprint International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations
    Manfred Kaufmann
    Department of Gynecology and Obstetrics, Goethe University, Frankfurt am Main, Germany
    J Clin Oncol 21:2600-8. 2003
    ..Recommendations are made regarding terminology, indications, regimen, diagnosis before treatment, monitoring of efficacy, tumor localization, surgery, pathologic evaluation, and postoperative treatment...
  33. ncbi request reprint The cost of life: should it matter to doctors?
    Luca Gianni
    Ann Oncol 17:357-8. 2006
  34. ncbi request reprint Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
    Giorgio Minotti
    G d Annunzio University School of Medicine, Centro Studi Sull Invecchiamento, Room 412, Via dei Vestini, 66013 Chieti, Italy
    Pharmacol Rev 56:185-229. 2004
    ..An overview of these issues confirms that anthracyclines remain "evergreen" drugs with broad clinical indications but have still an improvable therapeutic index...
  35. ncbi request reprint Future options with trastuzumab for primary systemic and adjuvant therapy
    Jose Baselga
    Vall d Hebron University, Barcelona, Spain
    Semin Oncol 31:51-7. 2004
    ..Together, this extensive program, which includes analysis of predictive molecular and pathologic makers, will establish the efficacy, safety, and role of trastuzumab in early breast cancer...
  36. ncbi request reprint Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies
    Emanuela Salvatorelli
    Department of Drug Sciences and Center of Excellence on Aging, G d Annunzio University School of Medicine, Via dei Vestini, 66013 Chieti, Italy
    J Pharmacol Exp Ther 318:424-33. 2006
    ..This information serves metabolic insights into the risk of cardiotoxicity induced by doxorubicin-taxane therapies...
  37. ncbi request reprint Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Martine J Piccart-Gebhart
    Medicine Department, Jules Bordet Institute, Blvd de Waterloo 125, 1000 Brussels, Belgium
    N Engl J Med 353:1659-72. 2005
    ..We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy...
  38. ncbi request reprint Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies
    Emanuela Salvatorelli
    Department of Drug Sciences and Center of Excellence on Aging, G d Annunzio University School of Medicine, Via dei Vestini, 66013 Chieti, Italy
    J Pharmacol Exp Ther 320:790-800. 2007
    ..The failure of paclitaxel or docetaxel to stimulate epirubicinol formation therefore uncovers an important determinant of the improved cardiac tolerability of epirubicin-taxane combinations...
  39. ncbi request reprint Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition
    Emanuela Salvatorelli
    Center of Excellence on Aging, G d Annunzio University School of Medicine, 66013 Chieti, Italy
    J Biol Chem 281:10990-1001. 2006
    ..These results uncover the molecular determinants of the reduced cardiotoxicity of epirubicin and serve mechanism-based guidelines to improving antitumor therapies...
  40. doi request reprint Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease
    Julie R Gralow
    Seattle Cancer Care Alliance, Department of Medicine, 825 Eastlake Ave, EMS G3 200, Seattle, WA 98109 1023, USA
    J Clin Oncol 26:814-9. 2008
    ..To review the state of the science with respect to preoperative systemic therapy and pathologic assessment in operable breast cancer...
  41. doi request reprint The "other" signaling of trastuzumab: antibodies are immunocompetent drugs
    Luca Gianni
    J Clin Oncol 26:1778-80. 2008
  42. ncbi request reprint Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing
    Cristiana Sessa
    Istituto Oncologico della Svizzera Italiana, Via Ospedale, 6500 Bellinzona, Switzerland
    Eur J Cancer 42:171-8. 2006
    ..These findings are in agreement with the presence of saturable absorption and metabolic induction. The peculiar pharmacokinetics and >99% protein binding discouraged further clinical development of oral SU006668 in humans...
  43. ncbi request reprint Technology insight: Emerging techniques to predict response to preoperative chemotherapy in breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston 77030 4009, USA
    Nat Clin Pract Oncol 1:44-50. 2004
    ..Here we review recent advances in the application of gene expression profiling to chemotherapy response prediction...
  44. ncbi request reprint Ixabepilone and the narrow path to developing new cytotoxic drugs
    Luca Gianni
    J Clin Oncol 25:3389-91. 2007
  45. ncbi request reprint Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors
    Patricia M LoRusso
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA
    Clin Cancer Res 9:2040-8. 2003
    ..o. administered ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced cancer...
  46. ncbi request reprint Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine
    Giulia Bianchi
    Medical Oncology A, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Eur J Cancer 41:1746-50. 2005
    ..In view of its effect in improving established paclitaxel- and cisplatin-neuropathy, we recommend ALC testing in preventing progression or revert symptoms during neurotoxic chemotherapy...